

## 2. 急性骨髓性白血病(小兒) 第2版

- 13) Smith FO, Alonzo TA, Gerbing RB, et al : Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891. *Leukemia* 19 (12) : 2054-2062, 2005.
- 14) Woods WG, Neudorf S, Gold S, et al : A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. *Blood* 97 (1) : 56-62, 2001.
- 15) Ravindranath Y, Yeager AM, Chang MN, et al : Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. *New Engl J Med* 334 (22) : 1428-1434, 1996.
- 16) Entz-Werle N, Suciu S, van der Werff ten Bosch J, et al : Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report. *Leukemia* 19(12) : 2072-2081, 2005.
- 17) Stevens RF, Hann IM, Wheatley K, et al : Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia : results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party. *Br J Haematol* 101(1) : 130-140, 1998.
- 18) Tomizawa D, Tabuchi K, Kinoshita A, et al : Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia : long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group. *Pediatr Blood Cancer* 49 (2) : 127-132, 2007.
- 19) Niewerth D, Creutzig U, Bierings MB, et al : A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. *Blood* 116 (13) : 2205-2214, 2010.
- 20) Oliansky DM, Rizzo JD, Aplan PD, et al : The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children : an evidence-based review. *Biol Blood Marrow Transplant* 13 (1) : 1-25, 2007.
- 21) Michel G, Rocha V, Chevret S, et al : Unrelated cord blood transplantation for childhood acute myeloid leukemia : a Eurocord Group analysis. *Blood* 102 (13) : 4290-4297, 2003.
- 22) Isoyama K, Oda M, Kato K, et al : Long-term outcome of cord blood transplantation from unrelated donors as an initial transplantation procedure for children with AML in Japan. *Bone Marrow Transplant* 45 (1) : 69-77, 2010
- 23) Sanz MA, Lo Coco F, Martin G, et al : Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia : a joint study of the PETHEMA and GIMEMA cooperative groups. *Blood* 96 (4) : 1247-1253, 2000.
- 24) Breccia M, Diverio D, Noguera NI, et al : Clinico-biological features and outcome of acute promyelocytic leukemia patients with persistent polymerase chain reaction-detectable disease after the AIDA front-line induction and consolidation therapy. *Haematologica* 89 (1) : 29-33, 2004.
- 25) Huang ME, Ye YC, Chen SR, et al : Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. *Blood* 72 (2) : 567-572, 1988.
- 26) de Botton S, Coiteux V, Chevret S, et al : Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy. *J Clin Oncol* 22 (8) : 1404-1412, 2004.
- 27) Fenaux P, Chastang C, Chevret S, et al : A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. *Blood* 94 (4) : 1192-1200, 1999.
- 28) Imaizumi M, Tawa A, Hanada R, et al : Prospective study of a therapeutic regimen with all-trans

- retinoic acid and anthracyclines in combination of cytarabine in children with acute promyelocytic leukaemia: the Japanese childhood acute myeloid leukaemia cooperative study. *Br J Haematol* 152 (1) : 89-98, 2011.
- 29) 廣田貴久, 藤本孟男, 片野直之ほか: 小児急性前骨髄球性白血病の治療研究 (第2報) All-Trans Retinoic Acid 間歇交代療法の長期治療成績. *臨床血液* 38 (11) : 1177-1182, 1997.
- 30) Chen GQ, Shi XG, Tang W, et al: Use of arsenic trioxide (As<sub>2</sub>O<sub>3</sub>) in the treatment of acute promyelocytic leukemia (APL) : I. As<sub>2</sub>O<sub>3</sub> exerts dose-dependent dual effects on APL cells. *Blood* 89 (9) : 3345-3353, 1997.
- 31) Fox E, Razzouk BI, Widemann BC, et al : Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. *Blood* 111 (2) : 566-573, 2008.
- 32) Breccia M, Lo-Coco F : Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy. *Expert Opinion on Biological Therapy* 11 (2) : 225-234, 2011.
- 33) Sanz MA, Grimwade D, Tallman MS, et al : Management of acute promyelocytic leukemia : recommendations from an expert panel on behalf of the European LeukemiaNet. *Blood* 113(9) : 1875-1891, 2009.
- 34) de Botton S, Fawaz A, Chevret S, et al : Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group. *J Clin Oncol* 23(1) : 120-126, 2004.
- 35) Dvorak CC, Agarwal R, Dahl GV, et al : Hematopoietic stem cell transplant for pediatric acute promyelocytic leukemia. *Biology of blood and marrow transplantation : Biol Blood Marrow Transplant* 14 (7) : 824-830, 2008.
- 36) Bourquin JP, Thornley I, Neuberg D, et al : Favorable outcome of allogeneic hematopoietic stem cell transplantation for relapsed or refractory acute promyelocytic leukemia in childhood. *Bone Marrow Transplant* 34 (9) : 795-798, 2004.
- 37) Gamis AS, Woods WG, Alonzo TA, et al : Children's Cancer Group Study 2891. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia : a report from the Children's Cancer Group Study 2891. *J Clin Oncol* 21 (18) : 3415-3422, 2003.
- 38) Creutzig U, Reinhardt D, Diekamp S, et al : AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. *Leukemia* 19 (8) : 1355-1360, 2005.
- 39) Kudo K, Kojima S, Tabuchi K, et al : Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia : the Japanese Childhood AML Cooperative Study Group. *J Clin Oncol* 25 (34) : 5442-5447, 2007.
- 40) Taga T, Shimomura Y, Horikoshi Y, et al : Continuous and high-dose cytarabine combined chemotherapy in children with Down syndrome and acute myeloid leukemia : Report from the Japanese Children's Cancer and Leukemia Study Group (JCCLSG) AML 9805 Down Study. *Pediatr Blood Cancer* 57 (1) : 36-40, 2011.
- 41) Abildgaard L, Ellebaek E, Gustafsson G, et al : Optimal treatment intensity in children with Down syndrome and myeloid leukaemia : data from 56 children treated on NOPHO-AML protocols and review of the literature. *Ann Haematol* 85 : 275-280, 2006.
- 42) Stevens RF, Hann IM, Wheatley K, et al : Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: Results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party. *Br J Haematol* 101 : 130-140,

2. 急性骨髓性白血病(小児) 第2版

1998.

- 43) Rubin CM, Mick R, Johnson FL: Bone marrow transplantation for the treatment of haematological disorders in Down's syndrome : toxicity and outcome. *Bone Marrow Transplantation* 18 : 533-540, 1996.
- 44) Meissner B, Borkhardt a, Dilloo D, et al : Relapse, not regimen-related toxicity, was the major cause of treatment failure in 11 children with Down syndrome undergoing haematopoietic stem cell transplantation for acute leukemia. *Bone Marrow Transplantation* 40 : 945-949, 2007.
- 45) Muramatsu H, Sakaguchi H, Taga T, et al : Reduced intensity conditioning in allogeneic stem cell transplantation for AML with Down syndrome. *Pediatr Blood Cancer* 61 (5) : 925-927, 2014.
- 46) Taga T, Saito AM, Kudo K, et al : Clinical characteristics and outcome of refractory/relapsed myeloid leukemia in children with Down syndrome. *Blood* 120 : 1810-1815, 2012.

## 各部会メンバー

### 急性骨髄性白血病（成人）第2版部会

神田 善伸\* 自治医科大学附属さいたま医療センター血液科

### 急性骨髄性白血病（小児）第2版部会

足立 壯一\* 京都大学医学研究科人間健康科学

富澤 大輔 東京医科歯科大学医学部附属病院小児科

長谷川大一郎 兵庫県立こども病院血液腫瘍科

高橋 浩之 済生会横浜市南部病院小児科

多賀 崇 滋賀医科大学小児科

湯坐 有希 東京都立小児総合医療センター血液・腫瘍科

### 急性リンパ性白血病（成人）第2版部会

宮村 耕一\* 名古屋第一赤十字病院血液内科

上田 恭典 公益財団法人大原記念倉敷中央医療機構倉敷中央病院血液内科・  
血液治療センター外来化学療法センター

### 急性リンパ性白血病（小児）第2版部会

康 勝好\* 埼玉県立小児医療センター血液・腫瘍科

### 骨髄異形成症候群（成人）第2版部会

森下 剛久\* 愛知県厚生連江南病院血液腫瘍内科

金丸 昭久 近畿大学血液・腎臓・膠原病内科

東條 有伸 東京大学医科学研究所先端医療研究センター分子療法分野

中尾 眞二 金沢大学大学院医学研究科細胞移植学

### 骨髄異形成症候群（小児）第2版部会

真部 淳\* 聖路加国際病院小児科

### 悪性リンパ腫（成人）第2版部会

小椋美知則\* 国立病院機構鈴鹿病院臨床検査科

### 悪性リンパ腫（小児）部会

森 鉄也\* 聖マリアンナ医科大学小児科学教室

### 多発性骨髄腫第2版部会

角南 一貴\* 独立行政法人国立病院機構岡山医療センター血液内科固形腫瘍部会

### 固形腫瘍（小児）部会

原 純一\* 大阪市立総合医療センター小児血液腫瘍科

\*部会長

